Gene genies: Oxford Biomedica and Homology Medicines create AAV business
Leading gene and cell therapy group, Oxford Biomedica, and Homology Medicines, have announced that the companies will establish...
January 28, 2022
by pharmatimes
Virica Biotech, Oxford Biomedica Enter R&D Partnership
To improve the manufacturing of lentiviral vector gene therapies using viral sensitizers.
January 24, 2022
by contractpharma
Oxford Biomedica and Novartis extend lentiviral vector manufacturing agreement
The new agreement extends to 2028 and allows Oxord Biomedica to work with other potential partners across all CAR-T targets
December 15, 2021
by CPhIonline
PhoreMost, Oxford Biomedica Announce Gene Therapy Discovery Collaboration
PhoreMost and Oxford Biomedica have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. Financial details of the agreement are not disclosed.
November 18, 2020
by americanpharmaceuticalreview
PhoreMost, Oxford Biomedica Enter CAR-T Collaboration
Aims to develop next-gen CAR-T cell therapies leveraging SITESEEKER and LentiVector platforms.
November 10, 2020
by contractpharma
Oxford Biomedica enters Covid-19 vaccine manufacturing deal
Oxford Biomedica will reserve capacity for the vaccine candidate in up to three manufacturing suites at its Oxbox facility.
September 2, 2020
by pharmaceutical-technology
Oxford Biomedica and Beam Therapeutics sign CAR-T deal
UK-based Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics for next-generation CAR-T therapeutics.
August 4, 2020
by pharmatimes
Oxford Biomedica Signs Collaboration Agreement with VMIC
Will work collaboratively to enable the manufacture of viral vector-based vaccines.
June 15, 2020
by contractpharma
Oxford Biomedica partners VMIC for vaccine manufacturing
UK-based gene and cell therapy group Oxford Biomedica has partnered with non-profit Vaccines Manufacturing and Innovation Centre (VMIC) for the manufacturing of viral vector-based vaccines.
June 9, 2020
by pharmaceutical-technology
Oxford Biomedica joins consortium for coronavirus vaccine
UK-based gene and cell therapy group Oxford Biomedica has become part of a consortium focussed on the development, scale-up and production of a Covid-19 coronavirus vaccine candidate.
April 9, 2020
by pharmaceutical-technology
Oxford Biomedica joins consortium for promising COVID-19 vaccine
As of this morning – Wednesday April 8 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 55,242 with 6,159 deaths
April 8, 2020
by pharmatimes
Oxford Biomedica to license LentiVector to Juno
Oxford Biomedica has signed a Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s Juno Theraputics, granting the latter a non-exclusive license to the LentiVector platform.
March 19, 2020
by pharmatimes